GSK is pressing ahead with a major global restructuring plan worth $2.5 billion, aimed at redirecting resources into late stage research and development. As part of this three year programme, the company is reducing more than 1,200 jobs across its Belgium sites in Rixensart, Wavre and Gembloux. This follows recent cuts of about 650 roles at its German vaccine-manufacturing facility.
The workforce changes will streamline research, manufacturing and support operations, with greater reliance on digital tools and automation. While specific roles have not been detailed, the impact will be felt across functions, requiring HR teams to manage redeployment, communication and morale during a period of uncertainty.
Despite the reductions, GSK will remain Belgium’s largest biopharma employer, with the country continuing to serve as a central hub for vaccine production. Belgium contributes more than half of GSK’s global vaccine output, underscoring its strategic importance even as operations are reshaped.
The company’s vaccine business remains strong, with sales rising 8 per cent year on year in the second quarter of 2026. Flagship products such as shingles vaccine Shingrix and respiratory vaccine Arexvy have delivered significant growth, alongside pipeline opportunities like an mRNA flu vaccine now in phase 3 trials.
The restructuring appears to be in response to the challenge of balancing business priorities with workforce stability. Managing large scale layoffs while sustaining engagement and retaining critical skills will be central to GSK’s ability to deliver on its innovation agenda. The company’s future growth depends not only on scientific breakthroughs but also on how effectively it supports employees through transformation.
